Construction and stable gene expression of AGR2xPD1 bi-specific antibody that enhances attachment between T-Cells and lung tumor cells, suppress tumor cell migration and promoting CD8 expression in cytotoxic T-cells

Roy, Debmalya; Liu, Guo-Song; Wang, Aru Zeling; Zhou, Bingjie; Yunus, Fakhar-un-Nisa; Raza, Ghulam Shere; Merugu, Siva Bharath; Mashausi, Dhahiri Saidi; Li, Dawei; Zhao, Bo

doi:10.1016/j.jsps.2022.11.007

Cited by 4 publications

(3 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, Roy et al demonstrated an augmented tumorkilling effect by developing BsAb-AGR2×PD1 for AGR2-positive cancers, intercepting AGR2 paracrine signaling, and rerouting cytotoxic T-cells towards AGR2+ cancer cells to reduce tumor cell viability [135]. These enhanced tumor-killing effects, primarily exploiting AGR2 overexpression in tumor cells, could enhance the efficacy of monoclonal antibody therapy [135]. We posit that AGR2 has already paved the way for novel discoveries regarding its therapeutic role in cancer.…”

Section: Agr2 and Clinical Treatmentmentioning

confidence: 92%

“…Moreover, AGR2 can be leveraged as a monoclonal antibody, such as 18A4, to enhance the efficacy of other cancer treatments, significantly augmenting the inhibitory impact of drugs on cancer cells [74]. For instance, Roy et al demonstrated an augmented tumorkilling effect by developing BsAb-AGR2×PD1 for AGR2-positive cancers, intercepting AGR2 paracrine signaling, and rerouting cytotoxic T-cells towards AGR2+ cancer cells to reduce tumor cell viability [135]. These enhanced tumor-killing effects, primarily exploiting AGR2 overexpression in tumor cells, could enhance the efficacy of monoclonal antibody therapy [135].…”

Section: Agr2 and Clinical Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

AGR2: The Covert Driver and New Dawn of Hepatobiliary and Pancreatic Cancer Treatment

Qu,

Jia,

Nie

et al. 2024

Biomolecules

View full text Add to dashboard Cite

The anterior gradient protein 2 (AGR2) plays a crucial role in facilitating the formation of protein disulfide bonds within the endoplasmic reticulum (ER). Research suggests that AGR2 can function as an oncogene, with its heightened expression linked to the advancement of hepatobiliary and pancreatic cancers through invasion and metastasis. Notably, AGR2 not only serves as a pro-oncogenic agent but also as a downstream targeting protein, indirectly fostering cancer progression. This comprehensive review delves into the established functions and expression patterns of AGR2, emphasizing its pivotal role in cancer progression, particularly in hepatobiliary and pancreatic malignancies. Furthermore, AGR2 emerges as a potential cancer prognostic marker and a promising target for immunotherapy, offering novel avenues for the treatment of hepatobiliary and pancreatic cancers and enhancing patient outcomes.

show abstract

Section: Agr2 and Clinical Treatmentmentioning

confidence: 92%

Section: Agr2 and Clinical Treatmentmentioning

confidence: 99%

AGR2: The Covert Driver and New Dawn of Hepatobiliary and Pancreatic Cancer Treatment

Qu,

Jia,

Nie

et al. 2024

Biomolecules

View full text Add to dashboard Cite

show abstract

“…Roy et al. ( 106 ) designed and synthesized BsAb AGR2xPD1, which showed higher anti-tumor response compared with the group of 18A4HU monoclonal antibody (mAb), the group of PD1 mAb and the combination treatment group of 18A4HU mAb and PD1 mAb. Wang et al.…”

Section: Potential Therapeutic Targets In Breast Cancermentioning

confidence: 99%

AGR2: a secreted protein worthy of attention in diagnosis and treatment of breast cancer

Zhang

Kong

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

AGR2 is a secreted protein widely existing in breast. In precancerous lesions, primary tumors and metastatic tumors, the expression of AGR2 is increased, which has aroused our interest. This review introduces the gene and protein structure of AGR2. Its endoplasmic reticulum retention sequence, protein disulfide isomerase active site and multiple protein binding sequences endow AGR2 with diverse functions inside and outside breast cancer cells. This review also enumerates the role of AGR2 in the progress and prognosis of breast cancer, and emphasizes that AGR2 can be a promising biomarker and a target for immunotherapy of breast cancer, providing new ideas for early diagnosis and treatment of breast cancer.

show abstract

Higher isoform of hnRNPA1 confer Temozolomide resistance in U87MG & LN229 glioma cells

Bhardwaj,

Sanjay,

Yadav

2024

J Neurooncol

View full text Add to dashboard Cite

Construction and stable gene expression of AGR2xPD1 bi-specific antibody that enhances attachment between T-Cells and lung tumor cells, suppress tumor cell migration and promoting CD8 expression in cytotoxic T-cells

Cited by 4 publications

References 32 publications

AGR2: The Covert Driver and New Dawn of Hepatobiliary and Pancreatic Cancer Treatment

AGR2: The Covert Driver and New Dawn of Hepatobiliary and Pancreatic Cancer Treatment

AGR2: a secreted protein worthy of attention in diagnosis and treatment of breast cancer

Higher isoform of hnRNPA1 confer Temozolomide resistance in U87MG & LN229 glioma cells

Contact Info

Product

Resources

About